Drugs / Anti-CD1a CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05745181 | Feb 2023 → Jan 2026 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD1a CAR-T | “Anti-CD1a CAR-T cells were transfused.” NCT05745181 ↗ |
| Known as | CD1a CAR-T | “This study intends to treat r/r CD1a+T-ALL/LBL with CD1a CAR-T to observe its safety and efficacy.” NCT05745181 ↗ |
| Modality | Cell therapy | “Anti-CD1a CAR-T cells were transfused.” NCT05745181 ↗ |